ATE375166T1 - Zusammensetzungen und verfahren zur behandlung von diabetes - Google Patents

Zusammensetzungen und verfahren zur behandlung von diabetes

Info

Publication number: ATE375166T1
Authority: AT; Austria
Prior art keywords: compositions; methods; treating diabetes; gastrin; treating
Prior art date: 2002-06-07

Application number

AT03757483T

Other languages

English (en)

Inventor

Stephen Brand

Antonio Cruz

Original Assignee

Waratah Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-07

Filing date

2003-06-09

Publication date

2007-10-15

2003-06-09 Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc

2007-10-15 Application granted granted Critical

2007-10-15 Publication of ATE375166T1 publication Critical patent/ATE375166T1/de

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 2
108010089448 Cholecystokinin B Receptor Proteins 0.000 abstract 1
102000004859 Cholecystokinin Receptors Human genes 0.000 abstract 1
108090001085 Cholecystokinin Receptors Proteins 0.000 abstract 1
102100021022 Gastrin Human genes 0.000 abstract 1
102000052874 Gastrin receptors Human genes 0.000 abstract 1
108010052343 Gastrins Proteins 0.000 abstract 1
230000008629 immune suppression Effects 0.000 abstract 1
229960003444 immunosuppressant agent Drugs 0.000 abstract 1
230000001861 immunosuppressant effect Effects 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000009707 neogenesis Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Transplantation (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT03757483T 2002-06-07 2003-06-09 Zusammensetzungen und verfahren zur behandlung von diabetes ATE375166T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38703202P	2002-06-07	2002-06-07
US43059002P	2002-12-03	2002-12-03

Publications (1)

Publication Number	Publication Date
ATE375166T1 true ATE375166T1 (de)	2007-10-15

Family

ID=29739925

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT03757483T ATE375166T1 (de)	2002-06-07	2003-06-09	Zusammensetzungen und verfahren zur behandlung von diabetes
AT07010865T ATE445407T1 (de)	2002-06-07	2003-06-09	Methoden und kompositionen um diabetes zu behandeln

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT07010865T ATE445407T1 (de)	2002-06-07	2003-06-09	Methoden und kompositionen um diabetes zu behandeln

Country Status (12)

Country	Link
US (3)	US7560425B2 (de)
EP (1)	EP1511509B1 (de)
JP (1)	JP2005533775A (de)
KR (1)	KR20050048542A (de)
CN (1)	CN1671407B (de)
AT (2)	ATE375166T1 (de)
AU (1)	AU2003243501A1 (de)
CA (1)	CA2486584A1 (de)
DE (2)	DE60329724D1 (de)
ES (1)	ES2334268T3 (de)
IL (2)	IL165285A0 (de)
WO (1)	WO2003103701A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
ES2315350T3 (es)	2001-01-12	2009-04-01	Waratah Pharmaceuticals Inc.	Composiciones para la introduccion de la neogenesis de islotes, que contienen unos ligandos para el receptor de gastrina/cck y ligandos para el receptor de efg.
US7037504B2 (en) *	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
JP2005527224A (ja) *	2002-05-24	2005-09-15	ワラタファーマシューティカルズ，インコーポレイテッド	糖尿病の処置
CA2486584A1 (en)	2002-06-07	2003-12-18	Waratah Pharmaceuticals, Inc.	Compositions and methods for treating diabetes
EP1837031B1 (de)	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methoden und Kompositionen um Diabetes zu behandeln
US20040229810A1 (en) *	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
KR20060006058A (ko) *	2003-04-22	2006-01-18	와이어쓰	항신생물성 배합물
US20080039379A1 (en) *	2003-05-27	2008-02-14	Waratah Pharmaceuticals, Inc.	Compositions Comprising Gastrin Compounds and Their Use in Diabetes
BRPI0507189A (pt) *	2004-01-30	2007-06-26	Waratah Pharmaceuticals Inc	uso combinado de um agonista de glp-1 e compostos de gastrina
WO2006002532A1 (en) *	2004-07-01	2006-01-12	Waratah Pharmaceuticals, Inc.	Methods and compositions using cd3 agonists
US8268791B2 (en) *	2004-08-25	2012-09-18	Aegis Therapeutics, Llc.	Alkylglycoside compositions for drug administration
US20140162965A1 (en)	2004-08-25	2014-06-12	Aegis Therapeutics, Inc.	Compositions for oral drug administration
US9895444B2 (en)	2004-08-25	2018-02-20	Aegis Therapeutics, Llc	Compositions for drug administration
US20060046962A1 (en)	2004-08-25	2006-03-02	Aegis Therapeutics Llc	Absorption enhancers for drug administration
CN104206651A (zh) *	2004-12-30	2014-12-17	希尔氏宠物营养品公司	用于猫消费的组合物
EP1951286A4 (de) *	2005-10-07	2009-11-04	Waratah Pharmaceuticals Inc	Kombinierte verwendung von dpp-iv-hemmern und gastrin-verbindungen
US10137083B2 (en) *	2006-03-07	2018-11-27	SGN Nanopharma Inc	Ophthalmic preparations
US11311477B2 (en) *	2006-03-07	2022-04-26	Sgn Nanopharma Inc.	Ophthalmic preparations
US8226949B2 (en)	2006-06-23	2012-07-24	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) *	2006-06-23	2012-05-08	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) *	2006-06-23	2009-12-31	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) *	2006-06-23	2011-12-27	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) *	2006-06-23	2008-09-16	Aegis Therapeutics, Inc.	Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) *	2006-06-23	2011-08-16	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
EP2040737A4 (de) *	2006-07-14	2013-05-29	Postech Acad Ind Found	Epidermaler wachstumsfaktor zur erhöhung der insulinsekretion und senkung des blutzuckers
US20090258865A1 (en)	2008-03-28	2009-10-15	Hale Biopharma Ventures, Llc	Administration of benzodiazepine compositions
CA2732228A1 (en) *	2008-07-25	2010-01-28	The Johns Hopkins University	Methods and compositions for treating and preventing autoimmune diseases
US8440631B2 (en)	2008-12-22	2013-05-14	Aegis Therapeutics, Llc	Compositions for drug administration
US8940705B2 (en)	2009-01-09	2015-01-27	The Regents Of The University Of California	Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone
PT3415139T (pt)	2011-06-14	2022-06-20	Neurelis Inc	Administração de benzodiazepina
HK1198467A1 (en) *	2011-08-03	2015-05-08	Zhongmin MA	Treatment of type 2 diabetes with fty720
US20130273089A1 (en)	2011-11-03	2013-10-17	Tolera Therapeutics, Inc.	Antibody and methods for selective inhibition of t-cell responses
BR112014010532A2 (pt)	2011-11-03	2017-04-18	Tolera Therapeutics Inc	anticorpo e métodos para inibição seletiva de respostas de célula-t
WO2014138003A1 (en) *	2013-03-04	2014-09-12	Neuralstem, Inc.	Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders
US11116777B2 (en)	2015-11-10	2021-09-14	City Of Hope	Conditioning regimens and methods for inducing mixed chimerism
WO2017116569A1 (en) *	2015-12-31	2017-07-06	City Of Hope	Methods for treating diabetes
US20210355448A1 (en) *	2017-06-26	2021-11-18	City Of Hope	Methods of islet cell culture
IL280198B2 (en) *	2018-07-18	2026-01-01	Regenxbio Inc	Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
JP7137696B2 (ja)	2019-05-14	2022-09-14	プロヴェンション・バイオ・インコーポレイテッド	１型糖尿病を予防するための方法および組成物
KR20230092863A (ko)	2020-06-11	2023-06-26	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es)	2021-05-24	2023-12-08	Provention Bio Inc	Metodos para el tratamiento de diabetes tipo 1.
EP4376866A4 (de) *	2021-06-10	2025-10-08	Fouad Kandeel	Zusammensetzungen und verfahren für inselzelltransplantate
CA3221395A1 (en)	2021-06-10	2022-12-15	Neurelis, Inc.	Methods and compositions for treating seizure disorders in pediatric patients

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL101353A0 (en)	1991-04-03	1992-11-15	American Home Prod	Pharmaceutical compositions for treating diabetes
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
US5885956A (en) *	1992-12-14	1999-03-23	Research Triangle Pharmaceuticals	Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US6558952B1 (en)	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
ES2185663T3 (es) *	1994-01-24	2003-05-01	Waratah Pharmaceuticals Inc	Tratamiento de la diabetes.
US5624895A (en) *	1994-02-18	1997-04-29	Georgetown University Medical Center	Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US20040037818A1 (en)	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
AU5027299A (en)	1998-07-31	2000-02-28	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes
US6610535B1 (en)	2000-02-10	2003-08-26	Es Cell International Pte Ltd.	Progenitor cells and methods and uses related thereto
JP2003528135A (ja)	2000-03-31	2003-09-24	プロバイオドラッグアーゲー	糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
ES2315350T3 (es)	2001-01-12	2009-04-01	Waratah Pharmaceuticals Inc.	Composiciones para la introduccion de la neogenesis de islotes, que contienen unos ligandos para el receptor de gastrina/cck y ligandos para el receptor de efg.
ES2298378T3 (es)	2001-06-28	2008-05-16	Novo Nordisk A/S	Formulacion estable de glp-1 modificado.
US7037504B2 (en) *	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
JP2005527224A (ja)	2002-05-24	2005-09-15	ワラタファーマシューティカルズ，インコーポレイテッド	糖尿病の処置
WO2004105780A2 (en)	2003-05-27	2004-12-09	Waratah Pharmaceuticals, Inc.	Compositions comprising gastrin compounds and their use in diabetes
EP1837031B1 (de)	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methoden und Kompositionen um Diabetes zu behandeln
CA2486584A1 (en)	2002-06-07	2003-12-18	Waratah Pharmaceuticals, Inc.	Compositions and methods for treating diabetes
MXPA05004202A (es)	2002-10-22	2005-09-20	Waratah Pharmaceuticals Inc	Tratamiento de la diabetes.
US20040229810A1 (en)	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
JP2007523840A (ja)	2003-04-30	2007-08-23	ワラタファーマシューティカルズ，インコーポレイテッド	ケラチノサイト増殖因子アゴニストおよびカストリン化合物を組み合わせた使用
BRPI0507189A (pt)	2004-01-30	2007-06-26	Waratah Pharmaceuticals Inc	uso combinado de um agonista de glp-1 e compostos de gastrina
WO2006002532A1 (en)	2004-07-01	2006-01-12	Waratah Pharmaceuticals, Inc.	Methods and compositions using cd3 agonists
EP1951286A4 (de)	2005-10-07	2009-11-04	Waratah Pharmaceuticals Inc	Kombinierte verwendung von dpp-iv-hemmern und gastrin-verbindungen
WO2007062531A1 (en)	2005-12-02	2007-06-07	Waratah Pharmaceuticals, Inc.	Combination treatments with gastrin agonists for diabetes and related diseases
WO2007095737A1 (en)	2006-02-21	2007-08-30	Waratah Pharmaceuticals Inc.	Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound

2003
- 2003-06-09 CA CA002486584A patent/CA2486584A1/en not_active Abandoned
- 2003-06-09 AT AT03757483T patent/ATE375166T1/de not_active IP Right Cessation
- 2003-06-09 IL IL16528503A patent/IL165285A0/xx unknown
- 2003-06-09 US US10/517,135 patent/US7560425B2/en not_active Expired - Fee Related
- 2003-06-09 KR KR1020047019788A patent/KR20050048542A/ko not_active Ceased
- 2003-06-09 CN CN038185261A patent/CN1671407B/zh not_active Expired - Fee Related
- 2003-06-09 AU AU2003243501A patent/AU2003243501A1/en not_active Abandoned
- 2003-06-09 WO PCT/US2003/018377 patent/WO2003103701A1/en not_active Ceased
- 2003-06-09 EP EP03757483A patent/EP1511509B1/de not_active Expired - Lifetime
- 2003-06-09 ES ES07010865T patent/ES2334268T3/es not_active Expired - Lifetime
- 2003-06-09 AT AT07010865T patent/ATE445407T1/de not_active IP Right Cessation
- 2003-06-09 JP JP2004510820A patent/JP2005533775A/ja active Pending
- 2003-06-09 DE DE60329724T patent/DE60329724D1/de not_active Expired - Lifetime
- 2003-06-09 US US10/457,126 patent/US20040023885A1/en not_active Abandoned
- 2003-06-09 DE DE60316798T patent/DE60316798T2/de not_active Expired - Lifetime
2004
- 2004-11-18 IL IL165285A patent/IL165285A/en not_active IP Right Cessation
2009
- 2009-04-08 US US12/420,212 patent/US20090269337A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7560425B2 (en)	2009-07-14
KR20050048542A (ko)	2005-05-24
IL165285A (en)	2010-04-29
US20060183674A1 (en)	2006-08-17
JP2005533775A (ja)	2005-11-10
DE60316798D1 (de)	2007-11-22
CN1671407A (zh)	2005-09-21
DE60329724D1 (de)	2009-11-26
ES2334268T3 (es)	2010-03-08
US20090269337A1 (en)	2009-10-29
US20040023885A1 (en)	2004-02-05
CA2486584A1 (en)	2003-12-18
EP1511509A1 (de)	2005-03-09
EP1511509A4 (de)	2005-04-27
DE60316798T2 (de)	2008-07-24
ATE445407T1 (de)	2009-10-15
IL165285A0 (en)	2005-12-18
AU2003243501A1 (en)	2003-12-22
WO2003103701A1 (en)	2003-12-18
CN1671407B (zh)	2010-05-26
EP1511509B1 (de)	2007-10-10

Legal Events

Date	Code	Title	Description
2008-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60316798D1 (de)	2007-11-22	Zusammensetzungen und verfahren zur behandlung von diabetes
DE60326002D1 (de)	2009-03-12	Behandlung von diabetes.
ATE539701T1 (de)	2012-01-15	Zusammengesetzte schlinge zur behandlung von inkontinenz
ATE404574T1 (de)	2008-08-15	Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
NO20013451L (no)	2001-07-12	1-Heterocyklus-substituerte diarylaminer
DE60321965D1 (de)	2008-08-14	Amidfunktionelle polymere, zusammensetzungen und verfahren
TR200103756T2 (tr)	2002-06-21	Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
TW200738270A (en)	2007-10-16	Method of treating depression using a TNFα antibody
WO2004034990A3 (en)	2004-07-08	Methods and compositions for use in treating cancer
ZA200701656B (en)	2008-09-25	Humanized anti-cment antagonists
TW200600087A (en)	2006-01-01	Methods and compositions for treating amyloid-related diseases
MXPA05014166A (es)	2006-03-13	Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
CY1112743T1 (el)	2016-02-10	Στερεοϊσομερως εμπλουτισμενες ενωσεις 3-αμινοκαρβονυλ δικυκλοεπτενο πυριμιδινοδιαμινης και οι χρησεις τους
DK1503794T3 (da)	2012-07-23	Behandlingsfremgangsmåder ved anvendelse af CTLA-4-antistoffer
TW200621256A (en)	2006-07-01	Formulations
IL195256A0 (en)	2009-08-03	Compositions of r(+)and s(-)pramipexole and methods of using the same
MXPA05010582A (es)	2005-11-23	Combinaciones antineoplasicas.
IL213523A0 (en)	2011-07-31	Compositions comprising blood group antigens
DE602004030621D1 (de)	2011-01-27	Verfahren und Vorrichtung zur Erzeugung von zusammengesetzen Benutzeroberflächen
ATE448775T1 (de)	2009-12-15	Rifalazil zur behandlung von infektionen mit clostridium difficile
DE602005012948D1 (de)	2009-04-09	Verfahren und zusammensetzungen zur behandlung von uveitis
TR199901104T2 (xx)	1999-07-21	Farmas�tik bile�ikler.
DE69915310D1 (de)	2004-04-08	Methoden zur behandlung der salzabhängigen hypertonie
NO20060093L (no)	2006-03-01	Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav
DK1189627T3 (da)	2004-02-16	Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden